Pharmacokinetic drug-drug interactions (PDDI), in which the pharmacokinetic clearance of one drug is altered by a coadministered drug, can be divided mechanistically into two general categories: 1. Inhibitory PDDI—the inhibition of the metabolic clearance of one drug by a coadministered drug, and 2. Inductive PDDI—the enhancement of the metabolic clearance of one drug by a coadministered drug. Three mechanism-based approaches are commonly used in the evaluation of the drug-drug interaction potential of a drug: 1. Identification of metabolic pathways, 2. Evaluation of the inhibitory potential for drug-metabolizing enzymes, and 3. Evaluation of the induction potential for drug-metabolizing enzymes. cDNA-expressed enzymes and microsomes are useful in the evaluation of metabolic pathways, especially in the identification of isozymes involved in metabolism. Microsomes, hepatocytes, and liver slices are useful in the evaluation of the inhibitory potential of the drug in question. Currently, primary hepatocytes represent the most relevant and useful preclinical system for the evaluation of the induction potential of a drug.
MonahanBPFergusonCLKilleavyESLloydBKTroyJCantilenaJr.LR. Torsades de pointes occurring in association with terfenadine use. JAMA.1990;264:2788–2790.
2.
FDA.Warnings issued on nonsedating antihistamines terfenadine and astemizole. JAMA.1992;268:705.
3.
Pohjala-SintonenSViitsaloMToivonenLNeuvonenP.Torsades de pointes after terfenadine-itraconazole interaction. Brit Med J.1993;306:186.
4.
YunCHOkerholmAGuengerichFPOxidation of the antihistamine drug terfenadine in human liver microsomes. Role of cytochrome P4503A (4) in N-dealkylation and C-hydroxylation. Drug Metab Disp.1993;21:403–409.
5.
WoosleyRLChenYFreimanJPGillisRAMechanism of the cardiotoxic actions of terfenadine. JAMA.1993;269:1532–1536.
6.
D'ArcyPFDrug interactions with oral contraceptives. Drug Intell Clin Pharm.1986;20:353–362.
7.
GrangeJMWinstanleyPADaviesPDClinically significant drug interactions with antituberculosis agents. Drug Saf.1994;11:242–251.
8.
Strolin BenedettiMDostertP.Induction and autoinduction properties of rifamycin derivatives: a review of animal and human studies. Environ Health Perspect.1994;102:101–105.
9.
GedCRoullionJMPichardLCombalbertJBressotNBoriesPMichelHBeaunePMaurelP.The increase in urinary excretion of 6β-hydroxycortisol as a marker of human hepatic cytochrome P450 IIIA induction. Br J Clin Pharmacol.1989;38:373–387.
10.
LiAPXuLRasmussenAKaminskiDLRifampicin induction of lidocaine metabolism in cultured human hepatocytes. J Pharmacol Exp Ther.1995;274:673–677.
11.
LiAPJurima-RometM.Applications of primary human hepatocytes in the evaluation of pharmacokinetic drug-drug interactions: evaluation of model drugs terfenadine and rifampin. Cell Biol Toxicol.1997;13:365–374.
12.
GuengerichFPMetabolism of 17a-ethynylestradiol in humans. Life Sci.1990;47:1981–1988.
13.
ReimersDNocke-FinckLBreuerH.Rifampicin and the “pill” do not go well together. JAMA.1974;227:608.
14.
BarbarashRAVerapamil-rifampin interaction. Drug Intell Clin Pharm.1985;19:559–560.
15.
FrommMFBusseDKroemerHKEichelbaumM.Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology.1996;24:796–801.
16.
HerbertMFRobertsJPPrueksaritanontTBenetLZBioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther.1992;52:453–457.
17.
LangRShashaBRubinsteinE.Therapy of experimental murine burcellosis with streptomycin alone and in combination with ciprofloxacin, doxycycline, and rifampin. Antimicrob Agents Chemother.1993;37:2333–2336.
18.
ColmeneroJDFernandez-GallardoLCAgundezJASedenoJBenitezJValverdeE.Possible implications of doxycycline-rifampin interaction in the treatment of brucellosis. Antimicrob Agents Chemother.1994;38:2798–2802.
19.
DraytonJDickinsonGRinaldiMGCoadministration of rifampin and itraconazole leads to undetectable levels of serum intraconazole (letter). Clin Infect Dis.1994;18:266.
20.
LeeKHShinJGChongWSKimSLeeJSJangIJShinSGTime course of the changes in prednisolone pharmacokinetics after coadministration or discontinuation of rifampin. Eur J Clin Pharmacol.1993;45:287–289.
21.
BurgerDMMeenhorstPLKoksCHBeijnenJHPharmacokinetic interaction between rifampin and zidovudine. Antimicrob Agents Chemother.1993;37: 1426–1431.
22.
GallicanoKSahaiJFosterBBouchardJCameronDWRifampin decreases zidovudine plasma concentrations in HIV infected patients. Abstract No. 425; 4th Conference on Retrovirus and Opportunistic Infections. Washington, DC: January 1997.
23.
RodriguesADUse of in vitro human metabolism studies in drug development: an industrial perspective. Biochem Pharmacol.1994;48:2147–2156.
24.
LiAPRoqueMABeckDJKaminskiDLIsolation and culturing of hepatocytes from human liver. J Tiss Culture Methods1992;14:139–146.
25.
GadAPPrimary hepatocyte culture as an in vitro toxicological system. In: LiShayne, ed. In Vitro Toxicology.New York, NY: Raven Press; 1994:195–220.
26.
LiAPPrimary hepatocyte cultures as an experimental model for the evaluation of pharmacokinetic drug-drug interactions. In: LiAlbert P., ed. Drug-drug interactions: scientific and regulatory perspectives.San Diego, CA; Academic Press; 1997:103–130.
27.
LiAPMaurelPGomez-LechonMJChengLCJurima-RometM.Preclinical evaluation of drug-drug interactions: present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 incution. Chemico-biological Interactions.1998;107:5–16.
28.
KrumdieckCLDosSantos JEHoKJA new instrument for the rapid preparation of tissue slices. Anal Biochem.1980;104:118–123.
29.
BrendelKGandolfiAJKrumdieckCLSmithPFTissue slicing and culturing revisited. Trends Pharm Sci.1987;8:11–15.
30.
VickersAEMFischerVConnorsSFisherRLBaldeckJPMaurerGBrendelK.Cyclosporin A metabolism in human liver, kidney, and intestine slices. Comparison to rat and dog slices and human cell lines. Drug Metab Dispos.1992;20:802–809.
31.
CrespiCLGonzalezFJSteimelDTTurnerTRGelboinHVPenmanBWLangenbachR.A meta-bolically competent cell line expressing five cDNAs encoding procarcinogen-activating enzymes: applications to mutagenicity testing. Chem Res Toxicol.1991;4:566–572.
32.
CrespiCLLangenbachRPenmanBWHuman cell lines, derived from AHH-1 TK+/- human lymphoblasts, genetically engineered for expression of cytochromes P450. Toxicol.1993;82:89–104.
33.
GillamEMJBabaTKimBROhmoriSGuengerichFPExpression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme. Arch Biochem Biophys.1993;305:123–131.
34.
ButlersJTMKorzekwaKRKunzeKLOmataYHarwickJPGonzalezFJcDNA-directed expression of human cytochrome P450 CYP3A4 using baculovirus. Drug Metab Disp.1994;22:688–692.
35.
GonzalezFJKorzekwaKRCytochromes P450 expression systems. Ann Rev Pharmacol Toxicol.1995;35:369–390.
36.
LiAPKaminskiDLRasmussenA.Substrates of human hepatic cytochrome P4503A4. Toxicol.1995a;104:1–8.
37.
WrightonSAVandenbrandenMStevensJCShipleyLARingBJIn vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metab Rev.1993;25:453–484.
38.
Jurima-RometMHuangHSBeckDJLiAPMetabolism of terfenadine and its inhibition in primary human and rat hepatocytes and HepG2 cells. Toxicol in Vitro.10:655–663.
